Vivani Medical has entered into an agreement for a private placement expected to generate approximately $5.1 million in gross proceeds before offering expenses.
Board Chairman Gregg Williams and director Aaron Mendelsohn agreed to purchase 5,049,506 shares of Vivani common stock at $1.01 per share. The transaction was priced at the market under applicable Nasdaq rules.
The private placement is expected to close on or around November 23, 2026, subject to customary closing conditions.
Vivani plans to use the net proceeds to fund research and clinical development of NPM-139, its semaglutide implant, along with other product candidates. A portion of the financing will also support working capital and general corporate needs.
The company expects the proceeds, combined with its existing cash, cash equivalents, and restricted cash, to fund operations into the third quarter of 2027.
Advancing NPM-139 Following Phase 1 Results
The financing follows Vivani’s announcement of positive top-line results from SLIM-1, its first human Phase 1 study of NPM-139.
The four-week, open-label, active-controlled trial enrolled 20 overweight or obese participants. Ten received a low dose of NPM-139, and ten received the initial 0.25-milligram weekly dose of injectable semaglutide.
Vivani reported no treatment-related adverse events among participants who received NPM-139. Five participants in the injectable semaglutide control group experienced treatment-related gastrointestinal events. No serious adverse events were reported, and implant insertion and removal procedures were completed without complications.
The results support plans for a Phase 2 dose-ranging study of NPM-139 in weight maintenance, which Vivani anticipates beginning in 2027.
Vivani’s NanoPortal platform is designed to deliver medicines steadily through miniature implants administered once or twice per year. Its pipeline focuses on GLP-1 therapies for obesity and Type 2 diabetes.

